Global Biosimilar Insulin Market Size By Type (Rapid Acting Insulins, Short Acting Insulins), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Biosimilar Insulin Market was valued at USD 3.9 billion in 2023 and is projected to surpass USD 9.2 billion by 2031, expanding at a CAGR of 11.3% during the forecast period of 2023–2031. The market is witnessing robust growth due to the rising prevalence of diabetes, growing demand for affordable insulin therapies, and supportive regulatory frameworks enabling the launch of biosimilar insulin products. As healthcare systems worldwide face increasing cost pressures, biosimilar insulin offers a cost-effective alternative to branded insulin therapies, improving accessibility for patients in both developed and emerging economies.

Drivers

Rising Global Diabetes Prevalence:

The increasing incidence of type 1 and type 2 diabetes globally is significantly boosting the demand for insulin. According to the International Diabetes Federation, over 537 million adults were living with diabetes in 2023, and the number is expected to rise sharply in the coming years, directly fueling the need for biosimilar insulin.

Cost Efficiency and Accessibility:

Biosimilar insulin is considerably more affordable than branded versions, making it a preferred choice in countries with limited healthcare budgets. The lower price point enhances accessibility, particularly in emerging markets, where insulin affordability is a major concern.

Supportive Regulatory Landscape:

Regulatory bodies such as the FDA and EMA have streamlined approval processes for biosimilars, encouraging more manufacturers to enter the market. This fosters competition, drives innovation, and supports widespread adoption of biosimilar insulin.

Restraints

Physician and Patient Reluctance:

Despite cost advantages, hesitancy among physicians and patients to switch from originator insulin to biosimilars continues to be a challenge, stemming from concerns regarding efficacy, safety, and interchangeability.

Stringent Manufacturing Requirements:

Biosimilar insulin production requires advanced biotechnological infrastructure, quality control, and compliance with rigorous regulatory standards, which pose significant barriers for new market entrants.

Opportunity

Market Penetration in Emerging Economies:

Emerging markets such as India, China, and Brazil present significant growth opportunities due to rising diabetes cases and a shift toward biosimilars to improve treatment affordability and reach.

Partnerships and Licensing Agreements:

Strategic collaborations between multinational pharmaceutical firms and regional players are enabling faster market entry and enhanced distribution capabilities. These partnerships are crucial for expanding global biosimilar insulin access.

Market by System Type Insights

Based on system type, the Long-Acting Biosimilar Insulin segment accounted for the largest market share in 2023. This is primarily due to its consistent demand for basal insulin therapy in type 2 diabetes management. Products like biosimilar glargine have seen widespread acceptance across healthcare systems, driven by strong clinical performance and cost competitiveness. Meanwhile, the Rapid-Acting Biosimilar Insulin segment is projected to grow at the fastest pace, fueled by rising insulin dependency and enhanced glycemic control requirements.

Market by End-use Insights

In terms of end-use, Hospitals and Clinics emerged as the dominant segment in 2023, accounting for more than 50% of the market share. This dominance is attributed to the higher patient footfall and robust reimbursement mechanisms in institutional settings. However, the Retail Pharmacies segment is anticipated to witness significant growth during the forecast period, driven by increasing consumer preference for at-home diabetes management and expanding pharmacy access to biosimilar products.

Market by Regional Insights

Regionally, North America held the largest share of the global biosimilar insulin market in 2023. The region's dominance is underpinned by its advanced healthcare infrastructure, favorable regulatory environment, and early adoption of biosimilars. On the other hand, the Asia-Pacific region is expected to register the fastest growth over the forecast period due to a rising diabetic population, government initiatives to improve healthcare access, and the expansion of local biosimilar manufacturing capabilities.

Competitive Scenario

Prominent players operating in the Global Biosimilar Insulin Market include Biocon Biologics Ltd., Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., Pfizer Inc., Merck & Co., Mylan N.V., Boehringer Ingelheim, Wockhardt Ltd., and Sandoz International GmbH. Key strategies adopted by these companies involve product launches, regulatory approvals, strategic alliances, and investments in R&D to expand their biosimilar insulin portfolios and global footprint.

Scope of Work – Global Biosimilar Insulin Market

Key Market Developments

2023: Biocon Biologics received FDA approval for its biosimilar insulin glargine product in the U.S., boosting access to affordable basal insulin therapy.

2024: Novo Nordisk expanded its biosimilar insulin production capabilities in Asia to meet growing regional demand.

2025: Pfizer partnered with a regional distributor in Latin America to expand its biosimilar insulin reach in underserved diabetic populations.

FAQs

1) What is the current market size of the Global Biosimilar Insulin Market?

The market was valued at USD 3.9 billion in 2023.

2) What is the major growth driver of the Global Biosimilar Insulin Market?

The major driver is the rising global prevalence of diabetes and the increasing demand for affordable insulin alternatives.

3) Which is the largest region during the forecast period in the Global Biosimilar Insulin Market?

North America is expected to remain the largest regional market during the forecast period.

4) Which segment accounted for the largest market share in the Global Biosimilar Insulin Market?

The Long-Acting Biosimilar Insulin segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Biosimilar Insulin Market?

Key players include Biocon Biologics, Eli Lilly, Sanofi, Novo Nordisk, Pfizer, and Sandoz, among others.